MENS (Jyong Biotech Ltd.) stock: $1.82, $138.4M market cap, $1.2M cash, $139.3M EV, $138.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
We commenced our commercial operations in July 2002 through Health Ever Bio-Tech Co., Ltd., which has been wholly owned by Jyong Biotech Ltd. since August 2018. In September 2019, we established Genvace Biotechnology Co., Ltd., a Taiwan subsidiary wholly owned by Health Ever Bio-Tech Co., Ltd. for the research and development of health products.
Status note Core drug candidate for BPH/LUTS; four Phase III trials conducted with API-1 (two pivotal, two open-label extensions, U.S. and Taiwan). FDA raised concerns about the U.S. pivotal trial and reproducibility of the Taiwan study; company plans an additional Phase III (MCS-2-US-b) with API-2, contingent on FDA acceptance of API-1/API-2 comparability and CMC documentation.
PCP
Phase 2 · Active
Indications
not disclosed(Phase 2)
Status note Key drug candidate; Phases I and II studies conducted with API-1. If API-2 is not shown comparable to API-1, Phase I/II studies would need repeating with API-2.
IC
Stage not disclosed · Active
Indications
not disclosed(Stage not disclosed)
Status note Named as a key drug candidate; no target, modality, indication, or stage detail disclosed in excerpts.
Per-asset detail extracted from the 20-F filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 718 stocks.